Saturday 17 October 2026 Export SCYX’s income statement to Excel — free account

SCYNEXIS, Inc.

SCYX Healthcare Drug Manufacturers Specialty & Generic

SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.67 0.24 −6.14%

Follow SCYX

Alert me

Market cap: $38.9M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: 5/9
Altman Z: −7.02
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	1	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.15%

Capital & Financial Ratios $m

Market Cap 38.90

Revenue 20.58

Net Income (10.23)

Free Cash Flow (13.31)

Net Debt (54.16)

Current Ratio 9.65

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.15)

P/S ratio 2.11

P/B ratio 0.65

Past 5Y EPS Growth —

This Y EPS Growth (113.97%)

Next Y EPS Growth 20.45%

Next Y revenue growth (96.99%)

Next 5Y EPS Growth (15.40%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.46%

10-year low 10-year high

P/B against its own 10 years 0.75%

10-year low 10-year high

EV/Sales against its own 10 years 11.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	75	60	40	54
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	22	10	—	—
	102	72	40	56

	2023	2024	2025	Q'26
Payables	7	5	2	3
ST’ Debt	—	—	—	—
Other	0	—	—	—
	16	24	6	6

Compound Annual Growth %

	10y	5y	3y
Sales	32.28%	179.40%	59.35%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.64%	16.76%	148.11%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	0	—	—	—
’25	0	1	0	19	21
’24	1	1	1	1	4
’23	1	131	2	6	140
’22	1	1	2	2	5
’21	12	—	1	1	13
’19	0	0	—	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(15)	—	—	—
’25	(7)	(7)	(9)	18	(5)
’24	(4)	(11)	1	(10)	(24)
’23	(19)	74	12	(8)	60
’22	(16)	(19)	(23)	(23)	(80)
’21	(1)	(12)	(17)	(26)	(55)
’20	(14)	(9)	(10)	(17)	(49)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(15)	—	—	—
’25	(7)	(7)	(9)	18	(5)
’24	(4)	(11)	1	(10)	(24)
’23	(19)	74	12	(8)	60
’22	(16)	(19)	(23)	(23)	(80)
’21	(1)	(12)	(17)	(26)	(56)
’20	(14)	(9)	(10)	(17)	(49)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.36)	0.63	—	—	—
’25	(0.88)	(1.12)	(1.36)	2.00	(1.36)
’24	0.08	(2.40)	(0.48)	(0.72)	(3.52)
’23	(5.68)	19.68	(0.32)	(3.12)	11.12
’22	(1.44)	(2.48)	(4.96)	(2.32)	(11.76)
’21	(1.41)	(1.76)	(0.17)	(8.40)	(10.00)
’20	(5.60)	(5.12)	0.54	(31.36)	(41.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	139.20	121.60	28.00	36.96	33.61	39.20	11.36	9.20	7.21	4.52	Analyst estimates 2026–2028 Powerpack
	High	528.00	305.60	196.00	152.00	96.80	82.00	54.16	30.96	24.56	11.92
People
People	Employees	14	19	24	27	38	56	36	29	28	18
	Revenue/emp, $m	0.02	0.01	0.01	0.00	0.00	0.24	0.14	4.83	0.13	1.14
Income, $m
Income, $m	Revenue	0	0	0	0	—	13	5	140	4	21
	Gross margin, %	100.00	100.00	100.00	100.00	0.00	97.63	87.66	88.85	100.00	100.00
	EBT	(30)	(25)	(19)	(54)	(58)	(36)	(68)	67	(21)	(9)
	EBT margin, %	(11,668.87)	(9,750.97)	(7,472.37)	(44,388.43)	0.00	(273.14)	(1,326.05)	47.94	(564.26)	(41.79)
	Net income	(30)	(25)	(12)	(54)	(55)	(33)	(63)	67	(21)	(9)
	Depreciation	0	0	0	1	1	2	2	4	2	0
Per share, $
Per share, $	Revenue	1.08	0.77	0.47	0.17	0.00	3.99	0.96	23.43	0.62	3.30
	Earnings	(126.40)	(75.20)	(22.40)	(76.80)	(41.20)	(10.00)	(11.76)	11.20	(3.52)	(1.36)
	Cash flow	(123.38)	(73.45)	(51.63)	(54.38)	(36.83)	(16.54)	(15.00)	10.06	(3.96)	(0.85)
	Capex	(0.11)	(0.01)	(1.03)	0.00	0.00	(0.36)	0.00	0.00	0.00	0.00
	Free cash flow	(123.50)	(73.46)	(52.66)	(54.38)	(36.83)	(16.90)	(15.00)	10.06	(3.96)	(0.85)
	Book value	146.36	64.04	56.92	18.40	16.98	12.51	0.61	12.20	9.08	7.91
	Shares, m	0	0	1	1	1	3	5	6	6	6
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	0.00	0.00	1.56	0.00	0.00
	P/S	251.79	237.26	82.31	274.37	—	12.23	12.05	0.75	15.67	1.53
	P/B	1.86	2.85	0.68	3.96	—	3.90	18.98	1.45	1.07	0.64
	EV/Sales	137.65	123.48	(2.44)	76.22	—	7.36	7.71	0.31	6.62	0.84
	EV/FCF	(1.20)	(1.29)	0.02	(0.37)	—	(1.74)	(0.49)	0.72	(1.03)	(3.27)
Cash, $m
Cash, $m	Operating cash flow	(29)	(25)	(28)	(38)	(49)	(55)	(80)	60	(24)	(5)
	Capex	0	0	(1)	—	0	(1)	0	—	—	—
	Free cash flow	(29)	(25)	(29)	(38)	(49)	(56)	(80)	60	(24)	(5)
Balance, $m
Balance, $m	Working capital	56	35	46	41	72	96	61	86	48	35
	Total debt	14	15	15	12	17	40	45	12	—	—
	Net debt	(44)	(29)	(29)	(37)	(77)	(64)	(28)	(63)	(60)	(40)
	Shareholders’ equity	35	21	31	13	23	41	3	73	55	49
Returns, %
Returns, %	ROA	(54.99)	(47.44)	(25.18)	(97.37)	(69.12)	(29.56)	(60.50)	62.01	(19.44)	(11.50)
	ROIC	0.00	0.00	(894.48)	0.00	0.00	0.00	0.00	437.60	0.00	(108.43)
	ROE	(78.13)	(89.14)	(47.38)	(243.47)	(309.57)	(102.68)	(282.34)	175.97	(33.25)	(16.48)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TLPH Talphera, Inc.	$55.5M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−33.11% (below 0%: shrinking)	100.00%	0.00%	Compare
INCR InterCure Ltd.	$55.1M	8.8×	— (loss-making)	−6.53% (below 0%: shrinking)	n/m	+389.50% (above 0%: growing)	32.04%	0.00%	Compare
ZYBT Zhengye Biotechnology Holding Limited	$44.6M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
Median of peers	$34.1M	—	—	−8.14%	—	+34.55%	32.04%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

SCYNEXIS, Inc. (SCYX) key facts

Strength: SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024.
SCYNEXIS, Inc. (SCYX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SCYX traded at $3.67, a market capitalization of $38.9 million.
Return on equity was −16.5% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −7.02 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.